Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective

Pharmaceutical Research

Volumn 14, Issue 11, 1997, Pages 1504-1510

  Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absorption; Drug discovery; High throughput; In vitro models; In vitro in vivo correlations; Metabolism; Screening

Indexed keywords

ANIMAL MODEL; AUTOMATION; CELL CULTURE; DATA BASE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; METHODOLOGY; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; PHARMACOKINETICS;

EID: 0031456698     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012105713585     Document Type: Review

References (37)

1. A. D. Rodrigues. Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48:2147-2156 (1994).
2. A. Parkinson. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 24:45-57 (1996).
3. L. S. Gan, E. C. Niederer, A. Bridgers, S. Yanni, P. H. Hsyu, F. J. Pritchard, and D. Thakker. Use of Caco-2 cells as an in vitro intestinal absorption and metabolism model. Drug Dev. Industrial Pharmacy 20:615-631 (1994).
4. L. A. Holland, N. P. Chetwyn, M. D. Perkins, and S. M. Lunte. Capillary electrophoresis in pharmaceutical analysis. Pharm. Res. 14:372-387 (1997).
5. J. C. Lindon, J. K. Nicholson, U. G. Sidelmann, and I. D. Wilson. Directly coupled HPLC-NMR and its application to drug metabolism. Drug Metab. Revs. 29:705-746 (1997).
6. J. Berman, K. Halm, K. Adkison, and J. Shaffer. Simultaneous pharmacokinetic screening of a mixture of compounds in dog using API LC/MS/MS analysis for increased throughput. J. Med. Chem. 40:827-829 (1997).
7. T. V. Olah, D. A. McLoughlin, and J. D. Gilbert. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmosphere pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun. Mass Spectrom. 11:17-23 (1997).
8. J. Singh, J. Soloweij, M. Allen, L. Killar, and M. Ator. Lead development: validation and application of high-throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors. Bioorg. Med. Chem. 4:639-643 (1996).
9. H. Kubinyi. Strategies and recent technologies in drug discovery. Pharmazie 50:647-662 (1995).
10. E. M. Gordon, M. A. Gallop, and D. V. Patel. Strategy and tactics in combinatorial organic synthesis. Applications to drug discovery. Acc. Chem. Res. 29:144-154 (1996).
11. A. Furka. History of combinatorial chemistry. Drug Devel. Res. 36:1-12 (1995).
12. L. J. Beeley, and D. M. Duckworth. The impact of genomics on drug design. Drug Discov. Today 1:474-480 (1996).
13. C. N. Selway and N. K. Terett. Parallel-compound synthesis: methodology for accelerating drug discovery. Bioorg. Med. Chem. 4:645-654 (1996).
14. D. Hook. Ultra high-throughput screening - a journey into nanoland with Gulliver and Alice. Drug Discov. Today 1:267-268 (1996).
15. M. W. Lutz, J. A. Menius, T. D. Choi, R. G. Laskody, P. L. Domanico, A. S. Goetz, and D. L. Saussy. Experimental design for high-throughput screening. Drug Discov. Today 1:277-286 (1996).
16. D. D. Bronson, D. M. Daniels, J. T. Dixon, C. C. Redick, and P. D. Haaland. Virtual kinetics: using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. Biochem. Pharmacol. 50:823-831 (1995).
17. Q. Zheng and D. J. Kyle. Computational screening of combinatorial libraries via multicopy sampling. Drug Discov. Today 2:229-234 (1997).
18. W. Rubas, M. E. M. Cromwell, R. J. Mrsny, G. Ingle, and K. A. Elias. An integrated method to determine epithelial transport and bioactivity of oral drug candidates in vitro. Pharm. Res. 13:23-26 (1996).
19. M. Chee, R. Yang, E. Hubbell, A. Berno, X. C. Huang, D. Stern, J. Winkler, D. J. Lockhart, M. S. Morris, and S. P. A. Fodor. Accessing genetic information with high-density DNA arrays. Science 274:610-614 (1996).
20. S. P. A. Fodor, J. L. Read, M. C. Pirrung, L. Stryer, A. T. Lu, and D. Solas. Light-directed, spatially addressable, parallel chemical synthesis. Science 251:767-773 (1991).
21. S. P. A. Fodor, R. Rava, X. C. Huang, A. C. Pease, C. P. Holmes, and C. L. Adams. Multiplexed biochemical assays with biochemical chips. Nature 364:555-556 (1993).
22. G. W. Bemis and M. A. Murcko. The properties of known drugs. 1: molecular frameworks. J. Med. Chem. 39:2887-2893 (1996).
23. D. F. V. Lewis. Molecular modelling of mammalian cytochromes P450. C. Ioannides (ed), Cytochromes P450: Metabolic and Toxicological Aspects, CRC Press, New York, 1996, pp 355-398.
24. D. F. V. Lewis, H. Moereels, B. G. Lake, C. Ioannides, and D. V. Parke. Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D. Drug Metab. Revs. 26:261-285 (1994).
25. J. B. Houston. Utility of m vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479 (1994).
26. P. Sanwald-Ducray and J. Dow. Prediction of pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 27:189-201 (1997).
27. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, and Y. Sugiyama. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17:273-310 (1996).
28. M. E. Brier and G. R. Aronoff. Application of artificial neural networks to clinical pharmacology. Int. J. Clin. Pharmacol. Ther. 34:510-514 (1996).
29. W. A. Ritschel, R. Akileswaran, and A. S. Hussain. Application of neural networks for the prediction of human pharmacokinetic parameters. Meth. Find. Exp. Clin. Pharmacol. 17:629-643 (1995).
30. R. J. Erb. The backpropagation neural network-a Bayesian classifier. Introduction and applicability to pharmacokinetics. Clin. Pharmacokin. 29:69-79 (1995).
31. G. S. Sittampalam, P. W. Iverson, I. A. Boadt, S. D. Kahl, S. Bright, J. M. Zock, W. P. Janzen, and M. D. Lister. Design of signal windows in high throughput screening assays for drug discovery. J. Biomol. Screening 2: 159-169 (1997).
32. M. Banks, A. Binnie, and S. Fogarty. High throughput screening using fully integrated robotic screening. J. Biomol. Screening 2: 133-135 (1997).
33. J. J. Bouska, R. L. Bell, C. L. Goodfellow, A. O. Stewart, C. D. W. Brooks, and G. W. Carter. Improving the in vivo duration of 5-lipoxygenase inhibitors: application of in vitro glucuronosyltransferase assay. Drug Metab. Dispos. 25: 1032-1038 (1997).
34. D. A. McLoughlin, T. V. Olah, and J. D. Gilbert. A direct method for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospekt solid-phase extraction system. J. Pharm. Biomed. Anal. 15: 1893-1901 (1997).
35. A. L. Ungell. In vitro absorption studies and their relevance to absorption from the GI tract. Drug Devel. Indust. Pharm. 23: 879-892 (1997).
36. M. Jansson, A. Emmer, J. Roeraade, U. Lindberg, and B. Hok. Micro vials on a silicon wafer for sample introduction in capillary electrophoresis. J. Chrom. 626: 310-314 (1992).
37. D. J. Harrison, K. Fluri, K. Seiler, Z. Fan, C. S. Effenhauser, and A. Manz. Micromachining a miniaturized capillary electrophoresis-based chemical analysis system on a chip. Science 261: 895-897 (1993).